4LEVI F, MISSET J L, BRIENZA S, et al. A chronopharmacologicphase Ⅱ clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory mul muhichannel programmadle pure. High antitumor effctiveness against metastate colorectal cancer[J]. Cancer, 1992,69(4):893 -900.
4Adelsberger H,Quasthoff S,Grosskreutz J,et al.The chemotherapeutic oxaliplatin alters voltage-gated Na(+)channel kinetics on rat sensory neurons[J].Eur J Pharmacol,2000,406(1):25-32
5Sarah Taieb, Louis Descos, Gilles Freyer, et al. Lhermitte sign and urinary retention-atypical presentation of oxaliplatin neurotoxicity in four patients[J]. Cancer, 2002,94(9) : 2434 - 2440.
6Misset JL. Oxaliplatin in practice [ J ] . Br J Cancer, 1998, 77(Suppl 4):S4- S7.
7Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin; a critical review[ J ] . Clin Cancer Res ,2000,6(4) : 1205 - 1218.
8Levi F, Metzger G, Massari C, et al. Oxaliplatin: pharmacokinetics and chronopharmacological aspeets[J]. Clin Pharmacokinet,2000,38(1) : 1 - 21.
9Luo FR, Wyrick SD, Charley SG. Biotransformations of oxaliplatin in rat blood in vitro[J] .J Biochem Mol Toxicol ,1999 ,13(3-4):159- 169.
10Gamelin E, LeBouil A, Boisdron-celle M, et al. Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-fluomuracil in colorectal cancer patients[J]. Clin Cancer Res, 1997,3(6) :891 - 899.
5Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J] . N Engl J Med, 2004, 350 (23) : 2343-2351.
6Levi F, Misset JL, Brienza S, etal. A chronopharmacologic phase, lI clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump: High antitumor effectiveness against metastatic colorectal cancer [J] . Cancer, 1992, 69 (4) : 893.
